DSM265 Prophylaxis of Plasmodium Falciparum Malaria
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The study is a single centre, randomised, placebo-controlled, double-blind study with DSM265
including up to two cohorts of healthy male and female volunteers aged 18 to 45 years.
The study will be conducted into two sequential parts (Cohort 1 and Cohorts 2a and 2b).
Phase:
Phase 1
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborators:
Center for Infectious Disease Research Fred Hutchinson Cancer Research Center United States Department of Defense